SOX2 and head and neck squamous cell carcinoma: In our previous work, Bayo&Jou et al., we showed that patients with the worst response to therapy have low SOX2 expression and that after SOX2 silencing, HNSCC cells acquire a mesenchymal-like phenotype and migrate more compared to control cells [18].